In 2017, the GLP-1 receptor agonist semaglutide was approved for type-2 diabetes treatment in the US, as an injection under the brand name Ozempic
The implementation of this non-invasive tool may help reduce risks to patients and potentially prevent unnecessary surgical cancellations in GLP-1RA users
Add a little more movement to your day As your weight goes down, your body uses less energy than it did before, which can reduce how many calories you burn each day
Our clinic uses an evidence-based, medical weight loss approach designed to: Reduce appetite, control hunger, cravings & food noise Improve metabolic function Support consistent, sustainable fat loss Clinically guided weight loss plan Ongoing provider support & monitoring Personalized strategy based on your history Simple, realistic lifestyle adjustments
Today, were taking a pivotal step forward in addressing some of the most pressing health issues of our time with the added indication for Wegovy, said Doug Langa, executive vice president, head of North America operations, and president of Novo Nordisk